![]() |
|||||||||||||
|
Home About CFCF Board of Directors Board of Patient Advisors Board of Scientific Advisors Carcinoid Community Carcinoid Information Clinical Trials Donations Friends of CFCF Events How You Can Help Memorials News Photo Gallery Research
Sponsors Sunflower |
Research RFPThe Caring for Carcinoid Foundation (CFCF) issues a Request for Proposal (RFP) prior to awarding research grants.CFCF's RFP are open to all scientists who undertake cutting-edge, genetically-based carcinoid / NET research. 2009 Request for ProposalNIH Challenge Grant: The Biology of Carcinoid and Related Neuroendocrine Tumors As part of the American Recovery and Investment Act of 2009 the NIH has designated at least 200 million for Challenge Grants in Health and Science Research. The Biology of carcinoid and related neuroendocrine tumors has been selected as a specific Challenge Topic under the Broad Challenge Area of Translation Research. Click here, to view this NIH announcement. Biology of carcinoid cancers and related neuroendocrine tumors (NETs).
Carcinoids and NETs are a heterogeneous group of tumors located largely in the
gastrointestinal system but also in other tissues including the pancreas and
lung. Carcinoid tumors originate in hormone-producing cells and can produce an
excess of a variety of hormones such as serotonin, bradykinin, histamine, and
prostaglandins, resulting in a diverse set of symptoms called "carcinoid
syndrome". However research in this area is highly understudied. Areas of
high research priorities include: Molecular insights for a better understanding
of cellular and molecular biology of neuroendocrine cells and mechanisms of
tumorigenesis; identification of molecular markers and improve imaging
modalities for early diagnosis, novel markers for identification of high-risk
patients and improve understanding of the natural history of this disease;
validation of neuroendocrine tumor models and cell lines to prove molecular
mechanism of tumor promotion and progression. The Caring for Carcinoid Foundation and The AGA Foundation for Digestive Health and Nutrition (FDHN) proudly announce a new research award for young investigators. Applications are now being accepted for the Mary Terese Hartzheim Award for Neuroendocrine Tumor Research, a new grant that provides $150,000 ($75,00 per year for two years) to young investigators researching biology of carcinoid or neuroendocrine tumors, and/or the development of novel therapeutic approaches to this group of diseases. Funded by the Caring for Carcinoid Foundation (CFCF), the object of the award is to expand interest and expertise in the field of neuroendocrine tumor research at academic medical institutions. Applicants must be within five years of completing their clinical or postdoctoral training, and must demonstrate a commitment to further research in this area. This grant is being awarded in honor of Mary Terese Hartzheim with the generous support of the MTH Foundation. For more information about this award, including complete eligibility criteria and a downloadable application, please visit the FDHN's Website at www.fdhn.org. This is the first time that the Caring for Carcinoid Foundation has partnered with the prestigious AGA and the MTH Foundation. Through this partnership we look forward to increased awareness, increased scientific interest, and scientific discovery to bring about novel treatments and diagnostics for patients. Prior Requests for Proposal2007 Request for Proposal
Research Grant Policies and Procedures |
|
|||||||||||
Click HERE to read Nancy Lindholm's New Blog
Click HERE to see our new Carcinoid Educational Brochure
Click HERE to see our new Neuroendocrine Tumor Educational Brochure
Click HERE to
see our new patient packet describing the Clinic for Carcinoid Cancer at The
Nebraska Medical Center
Click
HERE to listen to our new Expert Interview with Dr. Richard Baum of
Zentralklinic Bad Berka
Is it possible to cure carcinoid?
How long will it take to
cure carcinoid?
How much money will be needed to cure carcinoid?
Will achieving our mission benefit all carcinoid patients?